Cart
sales@molnova.com
Obinutuzumab/afutuzumab
CAS No. 949142-50-1
Obinutuzumab/afutuzumab( —— )
Catalog No. M22155 CAS No. 949142-50-1
Obinutuzumab GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 640 | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameObinutuzumab/afutuzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionObinutuzumab GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.
-
DescriptionObinutuzumab GA101) a novel glycoengineered Type II CD20 monoclonal antibody in development for non-Hodgkin lymphoma.
-
In VitroObinutuzumab is found to be superior to rituximab and ofatumumab in the induction of direct cell death (independent of mechanical manipulation required for cell aggregate disruption formed by antibody treatment), whereas it is 10 to 1,000 times less potent in mediating CDC. Obinutuzumab shows superior activity to rituximab and ofatumumab in ADCC and whole-blood B-cell depletion assays, and is comparable with these two in ADCP. Obinutuzumab also shows slower internalization rate upon binding to CD20 than rituximab and ofatumumab.
-
In VivoObinutuzumab is more active than rituximab administered at similar doses on established RL tumors. The antitumor effect of obinutuzumab against RL xenografts is dose dependent in terms of tumor growth inhibition (TGI). TGI is calculated using NCI formula at day 34 and shows values of 25, 75, and 85% for the 10, 30, and 100 mg/kg dosages of obinutuzumab, respectively. The higher doses of 30 and 100 mg/kg of obinutuzumab significantly inhibit the growth of RL tumors and result in some complete tumor remissions (10% and 30%, respectively). Tolerability of obinutuzumab with these regimens is excellent and no significant modification of body weight is observed. Obinutuzumab induces a strong antitumor effect, including complete tumor remission in the SU-DHL4 model and overall superior efficacy compared with both rituximab and ofatumumab. Obinutuzumab plus bendamustine achieves superior tumor growth inhibition versus rituximab plus bendamustine and shows a statistically significant effect versus the respective single treatments. Obinutuzumab plus chemotherapy is superior to the respective monotherapies.
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOther Targets
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number949142-50-1
-
Formula Weight150 kDa
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Herter S, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013 Oct;12(10):2031-42.
molnova catalog
related products
-
23-Butanedione
23-Butanedione (Diacetyl) the molecule implicated in the disease known as popcorn lung has now been implicated in amyloid-β peptide toxicity associated with Alzheimer’s disease. Diacetyl accelerates amyloid-β aggregation-a hallmark of Alzheimer’s disease.
-
2,5,6,7-Tetrahydroxy...
5,7,2 ',6 '-Tetrahydroxyflavanone is an extract isolated from Scutellaria baicalensis. 5,7,2 ',6 '-Tetrahydroxyflavanone has significant antibacterial activity against gram-positive bacteria. 5,7,2 ',6 '-Tetrahydroxyflavanone can be used to study the treatment of inflammatory diseases .
-
Ethanolamine hydroch...
Ethanolamine, a viscous, hygroscopic amino alcohol with an ammoniacal odor, is widely distributed in biological tissue and is a component of lecithin.
